Alembic Pharmaceuticals receives EIR for oncology facility

Alembic Pharmaceuticals Limited [BSE: 533573] announced today that it has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located in Panelav. The inspection, which was conducted between October 7th and October 8th, 2024, pertained to Alembic’s oncology formulation facility. The company confirmed this positive outcome following an earlier intimation dated October 9th, 2024, regarding the successful completion of the USFDA inspection. Alembic Pharmaceuticals has requested exchanges to note the record.